Experimental combo targets tough bone cancer in kids and adults
NCT ID NCT04833582
First seen Mar 21, 2026 · Last updated Apr 28, 2026 · Updated 3 times
Summary
This early-stage study tested a new drug (ZN-c3) combined with standard chemotherapy (gemcitabine) in 31 people aged 12 and older whose osteosarcoma (a type of bone cancer) had returned or stopped responding to treatment. The main goals were to check safety and see if the combination could slow or stop tumor growth. The study is complete, and results will help decide if further testing is warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 0103
Houston, Texas, 77030, United States
-
Site 0105
New York, New York, 10065, United States
-
Site 0106
Los Angeles, California, 90095, United States
-
Site 0107
Cincinnati, Ohio, 45229, United States
-
Site 0122
Seattle, Washington, 98195, United States
-
Site 0123
Portland, Oregon, 97239, United States
-
Site 0124
Oakland, California, 94609, United States
-
Site 0188
Richmond, Virginia, 23298, United States
-
Site 0193
Memphis, Tennessee, 38105, United States
-
Site 0195
Santa Monica, California, 90403, United States
-
Site 0197
Nashville, Tennessee, 37332, United States
-
Site 3601
Lyon, 69008, France
-
Site 3602
Marseille, 13385, France
-
Site 3604
Bordeaux, 33000, France
-
Site 3605
Toulouse, 31100, France
-
Site 3606
Paris, 75248, France
-
University of Florida College of Medicine
Gainesville, Florida, 32610, United States
Conditions
Explore the condition pages connected to this study.